ERNA Stock Price | Eterna Therapeutics Inc P/E, Revenue, EPS, & Forecasts

Eterna Therapeutics Inc • ERNA

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Eterna Therapeutics Inc

Ticker

ERNA

Trading on

NASDAQ

ISIN

Industry

Biotechnology

Sector

Healthcare

CEO

Sanjeev Luther

Headquarters

1035 Cambridge Street, Cambridge, MA, United States, 02141

Employees

Website

ernexatx.com

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Metrics

BasicAdvanced

Market cap

$13.4M

P/E ratio

EPS

-$17.76

Dividend Yield

0.00%

Beta

6.69

Forward P/E ratio

EBIDTA

$-9.9M

Ex dividend date

Price & volume

Market cap

$13.4M

Average daily volume

11M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

13,424.06

Price to book

2.1

Earnings

EPS

-$17.76

EPS estimate (current quarter)

$0.00

EPS estimate (next quarter)

$0.00

EBITDA

$-9.9M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

6.69

52-week High

$18.00

52-week Low

$1.09

50-day moving average

$1.32

200-day moving average

$2.64

Short ratio

0.26

Short %

0.63%

Management effectiveness

ROE (TTM)

-2,264.31%

ROA (TTM)

-89.29%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

-992,200.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

-94.10%

Share stats

Outstanding Shares

7.7M

Float

3.2M

Insiders %

59.71%

Institutions %

0.80%

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$140.00

-$60.00

-133.33%

Q4 • 92Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-3.1M

-∞%

Q2 • 25

$-1.2M

0.00%

Q3 • 25

NaN%

-60.60%

0.00%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$7.6M

$3.1M

41.40%

Q2 • 25

$6.2M

$2.6M

42.16%

Q3 • 25

-18.62%

-17.13%

1.82%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-2.5M

$0M

$4.9M

$-2.5M

Q2 • 25

$-1.3M

$0M

$-1.3M

Q3 • 25

-49.76%

-99.47%

-48.89%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Eterna Therapeutics Inc share?

Eterna Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Eterna Therapeutics Inc have?

Eterna Therapeutics Inc currently has 7.7M shares.

Does Eterna Therapeutics Inc pay dividends?

No, Eterna Therapeutics Inc doesn't pay dividends.

What is Eterna Therapeutics Inc 52 week high?

Eterna Therapeutics Inc 52 week high is $18.00.

What is Eterna Therapeutics Inc 52 week low?

Eterna Therapeutics Inc 52 week low is $1.09.

What is the 200-day moving average of Eterna Therapeutics Inc?

Eterna Therapeutics Inc 200-day moving average is $2.64.

Who is Eterna Therapeutics Inc CEO?

The CEO of Eterna Therapeutics Inc is Sanjeev Luther.

How many employees Eterna Therapeutics Inc has?

Eterna Therapeutics Inc has 6 employees.

What is the market cap of Eterna Therapeutics Inc?

The market cap of Eterna Therapeutics Inc is $13.4M.

What is the P/E of Eterna Therapeutics Inc?

The current P/E of Eterna Therapeutics Inc is null.

What is the EPS of Eterna Therapeutics Inc?

The EPS of Eterna Therapeutics Inc is -$17.76.

What is the PEG Ratio of Eterna Therapeutics Inc?

The PEG Ratio of Eterna Therapeutics Inc is null.